{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T02:38:40Z","timestamp":1773887920755,"version":"3.50.1"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["CA096297\/CA096300"],"award-info":[{"award-number":["CA096297\/CA096300"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006975","name":"Indiana Clinical and Translational Sciences Institute","doi-asserted-by":"publisher","award":["KL2 TR002530 and UL1 TR002529"],"award-info":[{"award-number":["KL2 TR002530 and UL1 TR002529"]}],"id":[{"id":"10.13039\/100006975","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009634","name":"Susan G. Komen","doi-asserted-by":"publisher","award":["CCR18548293"],"award-info":[{"award-number":["CCR18548293"]}],"id":[{"id":"10.13039\/100009634","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007544","name":"Boler Family Foundation","doi-asserted-by":"publisher","award":["endowment at University of Notre Dame"],"award-info":[{"award-number":["endowment at University of Notre Dame"]}],"id":[{"id":"10.13039\/100007544","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Penile squamous cell carcinoma (PSCC) accounts for over 95% of penile malignancies and causes significant mortality and morbidity in developing countries. Molecular mechanisms and therapies of PSCC are understudied, owing to scarcity of laboratory models. Herein, we describe a genetically engineered mouse model of PSCC, by co-deletion of <jats:italic>Smad4<\/jats:italic> and <jats:italic>Apc<\/jats:italic> in the androgen-responsive epithelium of the penis. Mouse PSCC fosters an immunosuppressive microenvironment with myeloid-derived suppressor cells (MDSCs) as a dominant population. Preclinical trials in the model demonstrate synergistic efficacy of immune checkpoint blockade with the MDSC-diminishing drugs cabozantinib or celecoxib. A critical clinical problem of PSCC is chemoresistance to cisplatin, which is induced by <jats:italic>Pten<\/jats:italic> deficiency on the backdrop of <jats:italic>Smad4\/Ap<\/jats:italic>c co-deletion. Drug screen studies informed by targeted proteomics identify a few potential therapeutic strategies for PSCC. Our studies have established what we believe to be essential resources for studying PSCC biology and developing therapeutic strategies.<\/jats:p>","DOI":"10.1038\/s41467-020-15980-9","type":"journal-article","created":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T10:02:39Z","timestamp":1588327359000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":62,"title":["Effective combinatorial immunotherapy for penile squamous cell carcinoma"],"prefix":"10.1038","volume":"11","author":[{"given":"Tianhe","family":"Huang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xi","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jad","family":"Chahoud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed","family":"Sarhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pheroze","family":"Tamboli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Priya","family":"Rao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6006-8961","authenticated-orcid":false,"given":"Ganiraju","family":"Manyam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7380-2640","authenticated-orcid":false,"given":"Leng","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoying","family":"Shang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pingna","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanting","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuemin","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shan","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magaly Martinez","family":"Ferrer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"Alan Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald A.","family":"DePinho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Curtis A.","family":"Pettaway","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0284-6478","authenticated-orcid":false,"given":"Xin","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,5,1]]},"reference":[{"key":"15980_CR1","doi-asserted-by":"publisher","first-page":"594","DOI":"10.6004\/jnccn.2013.0075","volume":"11","author":"PE Clark","year":"2013","unstructured":"Clark, P. E. et al. Penile cancer: clinical practice guidelines in oncology. J. Natl Compr. Cancer Netw. 11, 594\u2013615 (2013).","journal-title":"J. Natl Compr. Cancer Netw."},{"key":"15980_CR2","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1002\/ijc.21009","volume":"116","author":"JR Daling","year":"2005","unstructured":"Daling, J. R. et al. Penile cancer: Importance of circumcision, human papillomavirus and smoking in in situ and invasive disease. Int. J. Cancer 116, 606\u2013616 (2005).","journal-title":"Int. J. Cancer"},{"key":"15980_CR3","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/S1470-2045(18)30682-X","volume":"20","author":"TB Olesen","year":"2019","unstructured":"Olesen, T. B. et al. Prevalence of human papillomavirus DNA and p16INK4a in penile cancer and penile intraepithelial neoplasia: a systematic review and meta-analysis. Lancet Oncol. 20, 145\u2013158 (2019).","journal-title":"Lancet Oncol."},{"key":"15980_CR4","first-page":"478","volume":"103","author":"C Ferr\u00e1ndiz-Pulido","year":"2012","unstructured":"Ferr\u00e1ndiz-Pulido, C., de Torres, I. & Garc\u00eda-Patos, V. Penile squamous cell carcinoma. Actas Dermo-Sifiliogr.\u00e1ficas (Engl. Ed.) 103, 478\u2013487 (2012).","journal-title":"Actas Dermo-Sifiliogr.\u00e1ficas (Engl. Ed.)"},{"key":"15980_CR5","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1002\/ijc.21961","volume":"119","author":"AP Lont","year":"2006","unstructured":"Lont, A. P. et al. Presence of high-risk human papillomavirus DNA in penile carcinoma predicts favorable outcome in survival. Int. J. Cancer 119, 1078\u20131081 (2006).","journal-title":"Int. J. Cancer"},{"key":"15980_CR6","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/S1470-2045(07)70137-7","volume":"8","author":"O Kayes","year":"2007","unstructured":"Kayes, O., Ahmed, H. U., Arya, M. & Minhas, S. Molecular and genetic pathways in penile cancer. Lancet Oncol. 8, 420\u2013429 (2007).","journal-title":"Lancet Oncol."},{"key":"15980_CR7","doi-asserted-by":"publisher","first-page":"2236","DOI":"10.1016\/j.juro.2012.01.035","volume":"187","author":"CM Naumann","year":"2012","unstructured":"Naumann, C. M. et al. Establishment and characterization of primary cell lines of squamous cell carcinoma of the penis and its metastasis. J. Urol. 187, 2236\u20132242 (2012).","journal-title":"J. Urol."},{"key":"15980_CR8","doi-asserted-by":"crossref","unstructured":"Mu\u00f1oz J. J. D. S., Kuasne H., Villacis R. A., Marchi F. A., Domingues M. A., Lopes A., Santos T. G., Rogatto S. R. A comprehensive characterization of cell cultures and xenografts derived from a human verrucous penile carcinoma. Tumour Biol. 37, 11375\u201311384 (2016).","DOI":"10.1007\/s13277-016-4951-z"},{"key":"15980_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-018-0736-1","volume":"9","author":"QH Zhou","year":"2018","unstructured":"Zhou, Q. H. et al. Molecular characterization and integrative genomic analysis of a panel of newly established penile cancer cell lines. Cell Death Dis. 9, 684 (2018).","journal-title":"Cell Death Dis."},{"key":"15980_CR10","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1517\/17460441.2014.925875","volume":"9","author":"G Agarwal","year":"2014","unstructured":"Agarwal, G., Gupta, S. & Spiess, P. E. Novel targeted therapies for the treatment of penile cancer. Expert Opin. drug Discov. 9, 959\u2013968 (2014).","journal-title":"Expert Opin. drug Discov."},{"key":"15980_CR11","doi-asserted-by":"publisher","first-page":"3851","DOI":"10.1200\/JCO.2010.29.5477","volume":"28","author":"LC Pagliaro","year":"2010","unstructured":"Pagliaro, L. C. et al. Neoadjuvant paclitaxel, ifosfamide, and cisplatin chemotherapy for metastatic penile cancer: a phase II study. J. Clin. Oncol. 28, 3851\u20133857 (2010).","journal-title":"J. Clin. Oncol."},{"key":"15980_CR12","doi-asserted-by":"publisher","first-page":"S58","DOI":"10.1016\/j.urology.2010.03.082","volume":"76","author":"CA Pettaway","year":"2010","unstructured":"Pettaway, C. A., Pagliaro, L., Theodore, C. & Haas, G. Treatment of visceral, unresectable, or bulky\/unresectable regional metastases of penile cancer. Urology 76, S58\u2013S65 (2010).","journal-title":"Urology"},{"key":"15980_CR13","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1016\/j.urology.2014.12.049","volume":"85","author":"J Wang","year":"2015","unstructured":"Wang, J., Pettaway, C. A. & Pagliaro, L. C. Treatment for metastatic penile cancer after first-line chemotherapy failure: analysis of response and survival outcomes. Urology 85, 1104\u20131110 (2015).","journal-title":"Urology"},{"key":"15980_CR14","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s004410100464","volume":"307","author":"KS Kim","year":"2002","unstructured":"Kim, K. S. et al. Expression of the androgen receptor and 5 alpha-reductase type 2 in the developing human fetal penis and urethra. Cell Tissue Res 307, 145\u2013153 (2002).","journal-title":"Cell Tissue Res"},{"key":"15980_CR15","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1016\/S0022-5347(01)62700-9","volume":"160","author":"DN Tietjen","year":"1998","unstructured":"Tietjen, D. N., Uramoto, G. Y., Tindall, D. J. & Husmann, D. A. Characterization of penile androgen receptor expression in micropenis due to hypogonadotropic hypogonadism. J. Urol. 160, 1075\u20131078 (1998).","journal-title":"J. Urol."},{"key":"15980_CR16","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/S0925-4773(00)00551-7","volume":"101","author":"XWJ Wu","year":"2001","unstructured":"Wu, X. W. J., Huang, J., Powell, W. C., Zhang, J., Matusik, R. J., Sangiorgi, F. O., Maxson, R. E., Sucov, H. M. & Roy-Burman, P. Generation of a prostate epithelial cell-specific Cre transgenic mouse model for tissue-specific gene ablation. Mechanisms Dev. 101, 61\u201369 (2001).","journal-title":"Mechanisms Dev."},{"key":"15980_CR17","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1002\/dvg.20335","volume":"45","author":"MD Muzumdar","year":"2007","unstructured":"Muzumdar, M. D., Tasic, B., Miyamichi, K., Li, N. & Luo, L. A global double-fluorescent cre reporter mouse. Genesis 45, 593\u2013605 (2007).","journal-title":"Genesis"},{"key":"15980_CR18","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/S1535-6108(03)00215-0","volume":"4","author":"S Wang","year":"2003","unstructured":"Wang, S. et al. Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell 4, 209\u2013221 (2003).","journal-title":"Cancer Cell"},{"key":"15980_CR19","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/j.cell.2012.01.039","volume":"148","author":"Z Ding","year":"2012","unstructured":"Ding, Z. et al. Telomerase reactivation following telomere dysfunction yields murine prostate tumors with bone metastases. Cell 148, 896\u2013907 (2012).","journal-title":"Cell"},{"key":"15980_CR20","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/nature09677","volume":"470","author":"Z Ding","year":"2011","unstructured":"Ding, Z. et al. SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression. Nature 470, 269\u2013273 (2011).","journal-title":"Nature"},{"key":"15980_CR21","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.semcancer.2013.11.002","volume":"26","author":"M Tommasino","year":"2014","unstructured":"Tommasino, M. The human papillomavirus family and its role in carcinogenesis. Semin. Cancer Biol. 26, 13\u201321 (2014).","journal-title":"Semin. Cancer Biol."},{"key":"15980_CR22","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.virol.2009.10.011","volume":"396","author":"H Lichtig","year":"2010","unstructured":"Lichtig, H. et al. HPV16 E6 augments Wnt signaling in an E6AP-dependent manner. Virology 396, 47\u201358 (2010).","journal-title":"Virology"},{"key":"15980_CR23","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1158\/1541-7786.MCR-09-0345","volume":"8","author":"T Rampias","year":"2010","unstructured":"Rampias, T. et al. Activation of Wnt signaling pathway by human papillomavirus E6 and E7 oncogenes in HPV16-positive oropharyngeal squamous carcinoma cells. Mol. Cancer Res. 8, 433\u2013443 (2010).","journal-title":"Mol. Cancer Res."},{"key":"15980_CR24","doi-asserted-by":"publisher","first-page":"38557","DOI":"10.1074\/jbc.M206786200","volume":"277","author":"DK Lee","year":"2002","unstructured":"Lee, D. K., Kim, B.-C., Kim, I. Y., Cho E-a, Satterwhite, D. J. & Kim, S.-J. The human papilloma virus E7 oncoprotein inhibits transforming growth factor-\u03b2 signaling by blocking binding of the smad complex to its target sequence. J. Biol. Chem. 277, 38557\u201338564 (2002).","journal-title":"J. Biol. Chem."},{"key":"15980_CR25","doi-asserted-by":"publisher","first-page":"12420","DOI":"10.1128\/JVI.02576-05","volume":"80","author":"J-A Mendoza","year":"2006","unstructured":"Mendoza, J.-A., Jacob, Y., Cassonnet, P. & Favre, M. Human papillomavirus type 5 E6 oncoprotein represses the transforming growth factor \u03b2 signaling pathway by binding to SMAD3. J. Virol. 80, 12420\u201312424 (2006).","journal-title":"J. Virol."},{"key":"15980_CR26","doi-asserted-by":"publisher","first-page":"2490","DOI":"10.1158\/0008-5472.CAN-06-3028","volume":"67","author":"KJ Bruxvoort","year":"2007","unstructured":"Bruxvoort, K. J. et al. Inactivation of Apc in the mouse prostate causes prostate carcinoma. Cancer Res 67, 2490\u20132496 (2007).","journal-title":"Cancer Res"},{"key":"15980_CR27","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1038\/nature13305","volume":"511","author":"S Boumahdi","year":"2014","unstructured":"Boumahdi, S. et al. SOX2 controls tumour initiation and cancer stem-cell functions in squamous-cell carcinoma. Nature 511, 246\u2013250 (2014).","journal-title":"Nature"},{"key":"15980_CR28","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1158\/1078-0432.CCR-1032-3","volume":"10","author":"D Golijanin","year":"2004","unstructured":"Golijanin, D. et al. Cyclooxygenase-2 and microsomal prostaglandin E synthase-1 are overexpressed in squamous cell carcinoma of the penis. Clin. Cancer Res. 10, 1024\u20131031 (2004).","journal-title":"Clin. Cancer Res."},{"key":"15980_CR29","doi-asserted-by":"publisher","first-page":"5522","DOI":"10.1073\/pnas.96.10.5522","volume":"96","author":"M Shtutman","year":"1999","unstructured":"Shtutman, M. et al. The cyclin D1 gene is a target of the \u03b2-catenin\/LEF-1 pathway. Proc. Natl Acad. Sci. USA 96, 5522\u20135527 (1999).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"15980_CR30","first-page":"2167","volume":"27","author":"O Papadopoulos","year":"2007","unstructured":"Papadopoulos, O. et al. Expression of cyclin D1 and Ki-67 in squamous cell carcinoma of the penis. Anticancer Res 27, 2167\u20132174 (2007).","journal-title":"Anticancer Res"},{"key":"15980_CR31","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1038\/nature21676","volume":"543","author":"X Lu","year":"2017","unstructured":"Lu, X. et al. Effective combinatorial immunotherapy for castration-resistant prostate cancer. Nature 543, 728\u2013732 (2017).","journal-title":"Nature"},{"key":"15980_CR32","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/nature20554","volume":"539","author":"O De Henau","year":"2016","unstructured":"De Henau, O. et al. Overcoming resistance to checkpoint blockade therapy by targeting PI3K\u03b3 in myeloid cells. Nature 539, 443\u2013447 (2016).","journal-title":"Nature"},{"key":"15980_CR33","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/nature19834","volume":"539","author":"MM Kaneda","year":"2016","unstructured":"Kaneda, M. M. et al. PI3K\u03b3 is a molecular switch that controls immune suppression. Nature 539, 437\u2013442 (2016).","journal-title":"Nature"},{"key":"15980_CR34","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1016\/j.cell.2015.08.015","volume":"162","author":"S Zelenay","year":"2015","unstructured":"Zelenay, S. et al. Cyclooxygenase-dependent tumor growth through evasion of immunity. Cell 162, 1257\u20131270 (2015).","journal-title":"Cell"},{"key":"15980_CR35","doi-asserted-by":"crossref","unstructured":"Veltman J. D., et al. COX-2 inhibition improves immunotherapy and is associated with decreased numbers of myeloid-derived suppressor cells in mesothelioma. Celecoxib influences MDSC function. BMC Cancer 10, 464 (2010).","DOI":"10.1186\/1471-2407-10-464"},{"key":"15980_CR36","doi-asserted-by":"crossref","unstructured":"Surviladze Z., Sterk R. T., DeHaro S. A., Ozbun M. A. Cellular entry of human papillomavirus type 16 involves activation of the PI3K\/Akt\/mTOR pathway and inhibition of autophagy. J. Virol. 87, 2508\u20132517 (2012).","DOI":"10.1128\/JVI.02319-12"},{"key":"15980_CR37","doi-asserted-by":"publisher","first-page":"2030","DOI":"10.1016\/j.juro.2007.12.040","volume":"179","author":"P Andersson","year":"2008","unstructured":"Andersson, P., Kolaric, A., Windahl, T., Kirrander, P., S\u00f6derkvist, P. & Karlsson, M. G. PIK3CA, HRAS and KRAS gene mutations in human penile cancer. J. Urol. 179, 2030\u20132034 (2008).","journal-title":"J. Urol."},{"key":"15980_CR38","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1111\/his.12338","volume":"64","author":"A Chaux","year":"2014","unstructured":"Chaux, A. et al. Immunohistochemical expression of the mammalian target of rapamycin pathway in penile squamous cell carcinomas: a tissue microarray study of 112 cases. Histopathology 64, 863\u2013871 (2014).","journal-title":"Histopathology"},{"key":"15980_CR39","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1016\/j.juro.2013.06.015","volume":"190","author":"C Ferrandiz-Pulido","year":"2013","unstructured":"Ferrandiz-Pulido, C. et al. mTOR signaling pathway in penile squamous cell carcinoma: pmTOR and peIF4E over expression correlate with aggressive tumor behavior. J. Urol. 190, 2288\u20132295 (2013).","journal-title":"J. Urol."},{"key":"15980_CR40","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1038\/onc.2011.384","volume":"31","author":"L Galluzzi","year":"2012","unstructured":"Galluzzi, L. et al. Molecular mechanisms of cisplatin resistance. Oncogene 31, 1869\u20131883 (2012).","journal-title":"Oncogene"},{"key":"15980_CR41","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.ygyno.2004.11.051","volume":"97","author":"S Lee","year":"2005","unstructured":"Lee, S., Choi, E. J., Jin, C. & Kim, D. H. Activation of PI3K\/Akt pathway by PTEN reduction and PIK3CA mRNA amplification contributes to cisplatin resistance in an ovarian cancer cell line. Gynecol. Oncol. 97, 26\u201334 (2005).","journal-title":"Gynecol. Oncol."},{"key":"15980_CR42","doi-asserted-by":"publisher","first-page":"6325","DOI":"10.1158\/0008-5472.CAN-06-4261","volume":"67","author":"LZ Liu","year":"2007","unstructured":"Liu, L. Z., Zhou, X. D., Qian, G., Shi, X., Fang, J. & Jiang, B. H. AKT1 amplification regulates cisplatin resistance in human lung cancer cells through the mammalian target of rapamycin\/p70S6K1 pathway. Cancer Res. 67, 6325\u20136332 (2007).","journal-title":"Cancer Res."},{"key":"15980_CR43","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1074\/mcp.O113.034918","volume":"13","author":"R Akbani","year":"2014","unstructured":"Akbani, R. et al. Realizing the promise of reverse phase protein arrays for clinical, translational, and basic research: a workshop report: the RPPA (Reverse Phase Protein Array) society. Mol. Cell. Proteom. 13, 1625\u20131643 (2014).","journal-title":"Mol. Cell. Proteom."},{"key":"15980_CR44","doi-asserted-by":"crossref","unstructured":"Cubilla A. L., Lloveras B., Alejo M. Value of p16(INK)(4)(a) in the pathology of invasive penile squamous cell carcinomas: a report of 202 cases. Am. J. Surg. Pathol. 35, 253\u2013261 (2011).","DOI":"10.1097\/PAS.0b013e318203cdba"},{"key":"15980_CR45","first-page":"3991","volume":"8","author":"R Mukthavaram","year":"2013","unstructured":"Mukthavaram, R. et al. High-efficiency liposomal encapsulation of a tyrosine kinase inhibitor leads to improved in vivo toxicity and tumor response profile. Int. J. Nanomed. 8, 3991\u20134006 (2013).","journal-title":"Int. J. Nanomed."},{"key":"15980_CR46","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1111\/j.1442-2042.2006.01342.x","volume":"13","author":"J Nagasawa","year":"2006","unstructured":"Nagasawa, J., Mizokami, A., Koshida, K., Yoshida, S., Naito, K. & Namiki, M. Novel HER2 selective tyrosine kinase inhibitor, TAK-165, inhibits bladder, kidney and androgen-independent prostate cancer in vitro and in vivo. Int J. Urol. 13, 587\u2013592 (2006).","journal-title":"Int J. Urol."},{"key":"15980_CR47","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-015-0082-4","volume":"7","author":"H Kuasne","year":"2015","unstructured":"Kuasne, H. et al. Genome-wide methylation and transcriptome analysis in penile carcinoma: uncovering new molecular markers. Clin. Epigenetics 7, 46 (2015).","journal-title":"Clin. Epigenetics"},{"key":"15980_CR48","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1093\/annonc\/mdw216","volume":"27","author":"AM Udager","year":"2016","unstructured":"Udager, A. M. et al. Frequent PD-L1 expression in primary and metastatic penile squamous cell carcinoma: potential opportunities for immunotherapeutic approaches. Ann. Oncol. 27, 1706\u20131712 (2016).","journal-title":"Ann. Oncol."},{"key":"15980_CR49","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/s41585-018-0008-y","volume":"15","author":"S Matsushita","year":"2018","unstructured":"Matsushita, S. et al. Regulation of masculinization: androgen signalling for external genitalia development. Nat. Rev. Urol. 15, 358\u2013368 (2018).","journal-title":"Nat. Rev. Urol."},{"key":"15980_CR50","doi-asserted-by":"publisher","first-page":"E7194","DOI":"10.1073\/pnas.1515981112","volume":"112","author":"Z Zheng","year":"2015","unstructured":"Zheng, Z., Armfield, B. A. & Cohn, M. J. Timing of androgen receptor disruption and estrogen exposure underlies a spectrum of congenital penile anomalies. Proc. Natl Acad. Sci. USA 112, E7194\u2013E7203 (2015).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"15980_CR51","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1002\/ijc.2910580611","volume":"58","author":"K Uzawa","year":"1994","unstructured":"Uzawa, K. et al. Abnormalities of the adenomatous polyposis coli gene in human oral squamous-cell carcinoma. Int. J. Cancer J. Int. du Cancer 58, 814\u2013817 (1994).","journal-title":"Int. J. Cancer J. Int. du Cancer"},{"key":"15980_CR52","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1016\/j.oraloncology.2009.07.007","volume":"45","author":"G Supic","year":"2009","unstructured":"Supic, G., Kozomara, R., Brankovic-Magic, M., Jovic, N. & Magic, Z. Gene hypermethylation in tumor tissue of advanced oral squamous cell carcinoma patients. Oral. Oncol. 45, 1051\u20131057 (2009).","journal-title":"Oral. Oncol."},{"key":"15980_CR53","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.oraloncology.2011.09.001","volume":"48","author":"M Perez-Sayans","year":"2012","unstructured":"Perez-Sayans, M. et al. The role of the adenomatous polyposis coli (APC) in oral squamous cell carcinoma. Oral. Oncol. 48, 56\u201360 (2012).","journal-title":"Oral. Oncol."},{"key":"15980_CR54","doi-asserted-by":"publisher","first-page":"e0124395","DOI":"10.1371\/journal.pone.0124395","volume":"10","author":"M Arya","year":"2015","unstructured":"Arya, M. et al. Targets of Wnt\/ss-catenin transcription in penile carcinoma. PLoS One 10, e0124395 (2015).","journal-title":"PLoS One"},{"key":"15980_CR55","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/ng.2538","volume":"45","author":"LG Morris","year":"2013","unstructured":"Morris, L. G. et al. Recurrent somatic mutation of FAT1 in multiple human cancers leads to aberrant Wnt activation. Nat. Genet 45, 253\u2013261 (2013).","journal-title":"Nat. Genet"},{"key":"15980_CR56","doi-asserted-by":"publisher","first-page":"4720","DOI":"10.1158\/0008-5472.CAN-15-3134","volume":"76","author":"A Feber","year":"2016","unstructured":"Feber, A. et al. CSN1 somatic mutations in penile squamous cell carcinoma. Cancer Res. 76, 4720\u20134727 (2016).","journal-title":"Cancer Res."},{"key":"15980_CR57","first-page":"3408","volume":"119","author":"S Bornstein","year":"2009","unstructured":"Bornstein, S. et al. Smad4 loss in mice causes spontaneous head and neck cancer with increased genomic instability and inflammation. J. Clin. Invest 119, 3408\u20133419 (2009).","journal-title":"J. Clin. Invest"},{"key":"15980_CR58","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1016\/j.humpath.2010.11.010","volume":"42","author":"S Maier","year":"2011","unstructured":"Maier, S. et al. SOX2 amplification is a common event in squamous cell carcinomas of different organ sites. Hum. Pathol. 42, 1078\u20131088 (2011).","journal-title":"Hum. Pathol."},{"key":"15980_CR59","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.stem.2013.01.007","volume":"12","author":"K Liu","year":"2013","unstructured":"Liu, K. et al. Sox2 cooperates with inflammation-mediated Stat3 activation in the malignant transformation of foregut basal progenitor cells. Cell Stem Cell 12, 304\u2013315 (2013).","journal-title":"Cell Stem Cell"},{"key":"15980_CR60","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1038\/bjc.2014.528","volume":"111","author":"SH Lee","year":"2014","unstructured":"Lee, S. H. et al. SOX2 regulates self-renewal and tumorigenicity of stem-like cells of head and neck squamous cell carcinoma. Br. J. Cancer 111, 2122\u20132130 (2014).","journal-title":"Br. J. Cancer"},{"key":"15980_CR61","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.ccell.2016.09.001","volume":"30","author":"G Ferone","year":"2016","unstructured":"Ferone, G. et al. SOX2 is the determining oncogenic switch in promoting lung squamous cell carcinoma from different cells of origin. Cancer Cell 30, 519\u2013532 (2016).","journal-title":"Cancer Cell"},{"key":"15980_CR62","doi-asserted-by":"publisher","first-page":"17969","DOI":"10.1074\/jbc.M802917200","volume":"283","author":"Y Chen","year":"2008","unstructured":"Chen, Y. et al. The molecular mechanism governing the oncogenic potential of SOX2 in breast cancer. J. Biol. Chem. 283, 17969\u201317978 (2008).","journal-title":"J. Biol. Chem."},{"key":"15980_CR63","doi-asserted-by":"publisher","first-page":"2664","DOI":"10.1158\/0008-5472.CAN-10-3055","volume":"71","author":"M Fujita","year":"2011","unstructured":"Fujita, M. et al. COX-2 blockade suppresses gliomagenesis by inhibiting myeloid-derived suppressor cells. Cancer Res. 71, 2664\u20132674 (2011).","journal-title":"Cancer Res."},{"key":"15980_CR64","doi-asserted-by":"publisher","first-page":"5498","DOI":"10.1182\/blood-2011-07-365825","volume":"118","author":"N Obermajer","year":"2011","unstructured":"Obermajer, N., Muthuswamy, R., Lesnock, J., Edwards, R. P. & Kalinski, P. Positive feedback between PGE2 and COX2 redirects the differentiation of human dendritic cells toward stable myeloid-derived suppressor cells. Blood 118, 5498\u20135505 (2011).","journal-title":"Blood"},{"key":"15980_CR65","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1073\/pnas.1612920114","volume":"114","author":"V Prima","year":"2017","unstructured":"Prima, V., Kaliberova, L. N., Kaliberov, S., Curiel, D. T. & Kusmartsev, S. COX2\/mPGES1\/PGE2 pathway regulates PD-L1 expression in tumor-associated macrophages and myeloid-derived suppressor cells. Proc. Natl Acad. Sci. USA 114, 1117\u20131122 (2017).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"15980_CR66","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1038\/s41585-018-0083-0","volume":"15","author":"B McGregor","year":"2018","unstructured":"McGregor, B. & Sonpavde, G. Immunotherapy for advanced penile cancer - rationale and potential. Nat. Rev. Urol. 15, 721\u2013723 (2018).","journal-title":"Nat. Rev. Urol."},{"key":"15980_CR67","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1097\/CJI.0000000000000221","volume":"41","author":"DT Trafalis","year":"2018","unstructured":"Trafalis, D. T., Alifieris, C. E., Kalantzis, A., Verigos, K. E., Vergadis, C. & Sauvage, S. Evidence for efficacy of treatment with the anti-PD-1 mab nivolumab in radiation and multichemorefractory advanced penile squamous cell carcinoma. J. Immunother. 41, 300\u2013305 (2018).","journal-title":"J. Immunother."},{"key":"15980_CR68","doi-asserted-by":"crossref","unstructured":"Nadal R. M., et al. Results of phase I plus expansion cohorts of cabozantinib (Cabo) plus nivolumab (Nivo) and CaboNivo plus ipilimumab (Ipi) in patients (pts) with with metastatic urothelial carcinoma (mUC) and other genitourinary (GU) malignancies. J. Clin. Oncol. 36 (Suppl. 6S), abstr. 515 (2018).","DOI":"10.1200\/JCO.2018.36.6_suppl.515"},{"key":"15980_CR69","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1101\/gad.293449.116","volume":"31","author":"AT Boutin","year":"2017","unstructured":"Boutin, A. T. et al. Oncogenic Kras drives invasion and maintains metastases in colorectal cancer. Genes Dev. 31, 370\u2013382 (2017).","journal-title":"Genes Dev."},{"key":"15980_CR70","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1158\/2159-8290.CD-15-0224","volume":"6","author":"G Wang","year":"2016","unstructured":"Wang, G. et al. Targeting YAP-dependent MDSC infiltration impairs tumor progression. Cancer Disco. 6, 80\u201395 (2016).","journal-title":"Cancer Disco."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-020-15980-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-020-15980-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-020-15980-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T21:18:56Z","timestamp":1670275136000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-020-15980-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,1]]},"references-count":70,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["15980"],"URL":"https:\/\/doi.org\/10.1038\/s41467-020-15980-9","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,1]]},"assertion":[{"value":"18 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2124"}}